Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Merck & Co., Inc. — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $19.81, while Merck & Co., Inc. trades at $124.07 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | MRK | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $103.20 | $129.52 |
52-Week Low | $18.43 | $77.60 |
Market Cap | — | $298.31B |
Enterprise Value | — | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $19.46, down 0.87% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid consistent weekly dividends, with recent payouts ranging from $0.24 to $0.56 per share. Key support lies at $19, with resistance at $20. Recent news highlights YieldMax's weekly distribution announcements, but some articles express concern over the ETF's long-term performance despite its high yield.
The outlook for CONY hinges on its ability to sustain high distributions through options strategies on Coinbase stock. Risks include the underlying volatility of Coinbase and the potential for distribution cuts if option income declines. Investors should weigh the attractive yield against the fund's bearish price trend and dependence on a single stock's options market.
Merck (MRK) trades at $124.34, showing modest daily gains of 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 73.91% gross margins and has beaten earnings expectations in recent quarters. Recent acquisition activity, including the Terns Pharmaceuticals deal announced April 7, 2026, demonstrates strategic pipeline expansion in oncology.
Merck presents a compelling investment case with analyst consensus favoring bullish sentiment (67.57% buy ratings) and a $137.30 price target offering ~10% upside. However, rising debt levels and projected 2026 earnings decline warrant caution. The stock's premium valuation at 34x P/E requires sustained execution to justify current pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
